Aldeyra Therapeutics (ALDX) Other financing activities (2017 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Other financing activities came in at $1.1 million in Q4 2025, up 209.56% YoY from $350279.0 in Q4 2024, and up 5427.75% on a QoQ basis from $19616.0 in Q1 2025.
Aldeyra Therapeutics (ALDX) Other financing activities (2017 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 9 years of Other financing activities data on file, last reported at $1.1 million in Q4 2025.
- Quarterly Other financing activities rose 209.56% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 193.14% YoY) and the FY2025 annual result came in at $1.1 million, up 215.16% from the prior year.
- Other financing activities rose to $1.1 million in Q4 2025, from $19616.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $4.0 million in Q1 2021 to a low of -$4.6 million in Q4 2021.
- A 5-year average of $129038.7 and a median of $67793.0 in 2023 frame the typical range for Other financing activities.
- The widest YoY moves for Other financing activities: up 38890.17% in 2021, down 589.69% in 2021.
- Tracing ALDX's Other financing activities over 5 years: stood at -$4.6 million in 2021, then surged by 77.49% to -$1.0 million in 2022, then surged by 108.09% to $83027.0 in 2023, then surged by 321.89% to $350279.0 in 2024, then surged by 209.56% to $1.1 million in 2025.
- The last three Other financing activities figures came in at $1.1 million (Q4 2025), $19616.0 (Q1 2025), and $350279.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aldeyra Therapeutics | 90.18 Mn | 90.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 71,140.00 |
| Mar 31, 2026 | 71,140.00 |
| Dec 31, 2025 | 1.08 Mn |
| Dec 31, 2025 | 1.08 Mn |
| Mar 31, 2025 | 19,616.00 |
| Mar 31, 2025 | 19,616.00 |
| Dec 31, 2024 | 350,279.00 |
| Dec 31, 2024 | 350,279.00 |
| Dec 31, 2023 | 83,027.00 |
| Dec 31, 2023 | 83,027.00 |
| Sep 30, 2023 | 105,810.00 |
| Sep 30, 2023 | 105,810.00 |
| Jun 30, 2023 | -47,267.00 |
| Jun 30, 2023 | -47,267.00 |
| Mar 31, 2023 | 52,559.00 |
| Mar 31, 2023 | 52,559.00 |
| Dec 31, 2022 | -1.03 Mn |
| Dec 31, 2022 | -1.03 Mn |
| Sep 30, 2022 | 1.10 Mn |
| Sep 30, 2022 | 1.10 Mn |